The 52nd Annual Society of Hematology (ASH) Annual Meeting was held December 4th through 7th, 2010, in Orlando, Florida. This report summarizes presentations at the 2010 ASH Annual Meeting, organized by topics rather than by sessions, providing an overview of information on new drugs in development, clinical trial results, treatment by patient characteristics, e.g., transplant eligibility or stage of disease, risk stratification and staging, disease biology including bone disease and use of bisphosphonates, and maintenance therapy. Although maintenance therapy is summarized in its own section, some trials that include maintenance therapy are summarized in more relevant sections, as many trials are now including some kind of continuing treatment for at least some patients.
On December 3, the International Myeloma Foundation (IMF) and the Postgraduate Institute for Medicine sponsored a symposium that presented an overview of the most recent data from clinical trials to allow participants to provide better care for their patients with multiple myeloma. Dr. Brian G.M. Durie introduced the presenters and topics at the symposium. Summaries of these presentations are included under the appropriate headings.
Multiple myeloma was the topic of many presentations at ASH, including the following:
- Education sessions were held on advances in the basic science of plasma cell disorders and on supportive care in plasma cell dyscrasias.
- An education session on high risk hematologic diseases included a talk on ultra high-risk myeloma.
- A scientific session was conducted on therapeutic targeting of the myeloma stem cell.
- Over a dozen simultaneous oral sessions (comprising about 6 presentations each) were held specifically on myeloma, with many other sessions presenting related information on transplantation, venous thromboembolism, stem cell collection, tumor cell biology, and other topics of interest.
- Three poster sessions featured hundreds of posters about myeloma and related topics, e.g., transplantation, pharmacoeconomics, and new drugs in development.
Click on the PDF tab above to read and/or download the document.